BLU.TO - BELLUS Health Inc.

Toronto - Toronto Delayed Price. Currency in CAD
3.0300
+0.0200 (+0.66%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close3.0100
Open3.0000
Bid3.0200 x 0
Ask3.0300 x 0
Day's Range2.9900 - 3.2000
52 Week Range0.5400 - 3.3500
Volume209,892
Avg. Volume248,379
Market Cap478.61M
Beta (3Y Monthly)-0.70
PE Ratio (TTM)N/A
EPS (TTM)-0.0920
Earnings DateAug 6, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.77
  • What Kind Of Shareholder Owns Most BELLUS Health Inc. (TSE:BLU) Stock?
    Simply Wall St.2 days ago

    What Kind Of Shareholder Owns Most BELLUS Health Inc. (TSE:BLU) Stock?

    A look at the shareholders of BELLUS Health Inc. (TSE:BLU) can tell us which group is most powerful. Generally...

  • Business Wire3 days ago

    BELLUS Health Convenes KOL Meeting to Discuss the State of Chronic Cough Treatment

    BELLUS Health Inc. (BLU.TO) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that it will convene a Key Opinion Leader meeting to discuss chronic cough on Tuesday, July 16, 2019 in New York City. BELLUS Health will also provide clinical and regulatory updates on its lead P2X3 antagonist product candidate for the treatment of chronic cough, BLU-5937. Dr. Jacky Smith, MB, ChB, FRCP, PhD, is a Professor of Respiratory Medicine at the University of Manchester, UK and an Honorary Consultant at University Hospital of South Manchester NHS Foundation Trust.

  • Business Wire2 months ago

    BELLUS Health Presents Phase 1 Data for BLU-5937, its Lead Product Candidate for the Treatment of Refractory Chronic Cough, at the American Thoracic Society International Conference

    BELLUS Health Inc. (BLU.TO) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today presented results from the clinical Phase 1 study of BLU-5937, an orally-administered P2X3 antagonist, being developed for the treatment of refractory chronic cough. Clinical data presented at the American Thoracic Society International Conference in Dallas, Texas showed that BLU-5937 is well-tolerated and importantly, provide the first clinical evidence that a highly selective P2X3 antagonist is associated with little to no impact on taste.

  • Business Wire2 months ago

    BELLUS Health to Present at Three Upcoming Healthcare Investor Conferences

    BELLUS Health Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, President and Chief Executive Officer of BELLUS Health, will present a corporate overview of the Company, including an update on its lead program BLU-5937 for the treatment of chronic cough, ...

  • Associated Press2 months ago

    Bellus: 1Q Earnings Snapshot

    The Laval, Quebec-based company said it had a loss of 2 cents per share. The drug developer posted revenue of $6,800 in the period. Its adjusted revenue was $7,000. The company's shares closed at $1.03. ...

  • Business Wire2 months ago

    BELLUS Health Provides Update on Its Chronic Cough Drug Candidate BLU-5937 and Reports Financial and Operating Results for the First Quarter Ended March 31, 2019

    BELLUS Health Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today provided an update on BLU-5937, its lead drug candidate for refractory chronic cough, and reported its financial and operating results for the first quarter ended March 31, 2019.

  • How Much Did BELLUS Health Inc.'s (TSE:BLU) CEO Pocket Last Year?
    Simply Wall St.3 months ago

    How Much Did BELLUS Health Inc.'s (TSE:BLU) CEO Pocket Last Year?

    Roberto Bellini became the CEO of BELLUS Health Inc. (TSE:BLU) in 2010. First, this article will compare CEO compensation with compensation at similar sized companies. Then we'll look at a snap shot of the business growt...

  • CNW Group3 months ago

    BELLUS Health to Present at Two Upcoming Healthcare Investor Conferences

    BELLUS Health to Present at Two Upcoming Healthcare Investor Conferences

  • CNW Group3 months ago

    BELLUS Health Announces Clearance of U.S. IND for BLU-5937 Phase 2 Study in Chronic Cough Patients

    LAVAL, QC , April 3, 2019 /CNW/ - BELLUS Health Inc. (BLU.TO) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that the U.S. Food and Drug Administration ("FDA") has accepted the Company's Investigational New Drug ("IND") application, thus clearing the start of its Phase 2 study for BLU-5937 in chronic cough patients in the United States . "We're very pleased that our first interactions with U.S. regulators have been positive and look forward to treating chronic cough patients with BLU-5937 shortly," commented Roberto Bellini , President and CEO of BELLUS Health. BELLUS Health expects to initiate the clinical Phase 2 study for BLU-5937 in chronic cough patients in mid-2019, with top-line results anticipated in mid-2020.

  • Is BELLUS Health’s (TSE:BLU) Share Price Gain Of 244% Well Earned?
    Simply Wall St.4 months ago

    Is BELLUS Health’s (TSE:BLU) Share Price Gain Of 244% Well Earned?

    Unfortunately, investing is risky - companies can and do go bankrupt. On the other hand, if you find a high quality business to buy (at the right price) you canRead More...

  • CNW Group5 months ago

    BELLUS Health Presents 2018 Highlights and 2019 Corporate Plan

    LAVAL, QC , Feb. 21, 2019 /CNW/ - BELLUS Health Inc. (BLU.TO) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for conditions with high unmet medical need, today presented its 2018 achievements and corporate priorities for 2019. The Company also reported its financial and operating results for the year ended December 31, 2018 . "The positive Phase 1 data reinforces our position that our lead drug candidate BLU-5937 has the potential to be a best-in-class therapeutic for the treatment of chronic cough," said Roberto Bellini , President and CEO of BELLUS Health.

  • Should You Be Concerned About BELLUS Health Inc.’s (TSE:BLU) Historical Volatility?
    Simply Wall St.5 months ago

    Should You Be Concerned About BELLUS Health Inc.’s (TSE:BLU) Historical Volatility?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you're interested in BELLUS Health Inc. Read More...

  • GlobeNewswire7 months ago

    BELLUS Health Announces Payment of $134,149 to Thallion CVR Holders

    BELLUS Health Inc. (BLU.TO) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for conditions with high unmet medical needs, today announced that it will pay an amount of $134,149 to the Contingent Value Rights (“CVR”) holders as provided in the agreements of the 2013 Thallion Pharmaceuticals Inc. (“Thallion”) acquisition by BELLUS Health. In accordance with the terms of the agreements of the 2013 Thallion acquisition, Thallion’s income tax credits deducted in the 2013 Thallion Statement of Net Cash are now payable to the CVR holders as they were not claimed by tax authorities after their audit or their assessment period expired (the “Income Tax Credits”). Accordingly, on January 25, 2019, a net amount of $134,149 ($0.00374 per CVR) will be paid to the CVR holders of record on December 28, 2018, which consists of the Income Tax Credits of $159,603 less $25,454 for CVR agent costs.

  • GlobeNewswire7 months ago

    BELLUS Health Closes $35M Financing to Support Development of its Lead Drug Candidate BLU-5937 for Chronic Cough

    BELLUS Health Inc. (BLU.TO) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it has closed an equity offering, issuing a total of 36,842,105 common shares for gross proceeds of $35 million (the "Offering"). The Offering was led by OrbiMed and also included New Leaf Venture Partners, First Manhattan Co., Samsara BioCapital, Fonds de solidarité FTQ, AppleTree Partners and Amzak Health. In connection with the financing, Mr. Chau Q. Khuong, Partner at OrbiMed, has joined the Company’s Board of Directors.

  • ACCESSWIRE7 months ago

    Today's Research Reports on Aptose Biosciences, ProMIS Neurosciences, Emblem and BELLUS Health

    NEW YORK, NY / ACCESSWIRE / December 18, 2018 / The Market Edge strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us ...

  • CNW Group7 months ago

    IIROC Trade Resumption - BLU

    IIROC Trade Resumption - BLU

  • CNW Group7 months ago

    IIROC Trading Halt - BLU

    IIROC Trading Halt - BLU

  • GlobeNewswire7 months ago

    BELLUS Health Announces Pricing of $35 Million Public Offering of Common Shares

    BELLUS Health Inc. (BLU.TO) (BELLUS Health or the Company), a clinical-stage biopharmaceutical company developing novel therapeutics for conditions with high unmet medical need, today announced the pricing of its overnight marketed equity offering of $35 million of common shares at a price of $0.95 per share. The offering is being led by Bloom Burton Securities Inc., on behalf of a syndicate of agents that includes Mackie Research Capital Corporation and is to be effected on a best efforts basis in each of the Canadian provinces by way of a prospectus supplement to BELLUS Health's amended and restated base shelf prospectus dated November 30, 2018. In addition, the common shares may also be offered for sale in the United States through one or more United States registered broker-dealer(s) appointed by the agents as sub-agent(s) pursuant to exemptions from the registration requirements of the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) and applicable state laws.

  • GlobeNewswire7 months ago

    BELLUS Health Announces Overnight Marketed Equity Offering

    BELLUS Health Inc. (BLU.TO) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for conditions with high unmet medical need, today announced that it will undertake an overnight marketed offering of common shares. Bloom Burton Securities Inc. is acting as lead agent on behalf of a syndicate of agents that includes Mackie Research Capital Corporation. In addition, the common shares may also be offered for sale in the United States through one or more United States registered broker-dealer(s) appointed by the agents as sub-agent(s) pursuant to exemptions from the registration requirements of the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) and applicable state laws.

  • GlobeNewswire8 months ago

    BELLUS Health Announces Positive Top-Line Phase 1 Results for its Chronic Cough Drug Candidate BLU-5937

    BELLUS Health Inc. (BLU.TO) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for conditions with high unmet medical need, today announced positive top-line results from the clinical Phase 1 study for BLU-5937, its lead drug candidate for the treatment of chronic cough. The Phase 1 top-line data demonstrated that BLU-5937 has a good safety and tolerability profile, as well as a pharmacokinetic profile supporting twice-a-day (BID) dosing.

  • ACCESSWIRE8 months ago

    Today's Research Reports on TSO3, Emerald Health Therapeutics, Emblem and BELLUS Health

    NEW YORK, NY / ACCESSWIRE / November 16, 2018 / MarketEdge Report strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with ...

  • Simply Wall St.8 months ago

    How Financially Strong Is BELLUS Health Inc (TSE:BLU)?

    BELLUS Health Inc (TSE:BLU), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is BLU Read More...

  • CNW Group9 months ago

    BELLUS Health Announces Issuance of New U.S. Patent Claiming P2X3 Selectivity as a Means of Minimizing Taste Effects for its Lead Chronic Cough Drug Candidate BLU-5937

    LAVAL, QC , Oct. 31, 2018 /CNW/ - BELLUS Health Inc. (BLU.TO) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for conditions with high unmet medical need, today announced that the U.S. Patent and Trademark Office has issued U.S Patent No. 10,111,883, granting claims for the use of BELLUS Health's lead drug candidate BLU-5937 for the treatment of chronic cough without affecting taste response. More generally, the patent entitled "Selective P2X3 Modulators" claims the use of imidazopyridine compounds that are selective for the P2X3 receptor as a means of minimizing taste perturbation in patients treated for chronic cough. This patent adds to BLU-5937's intellectual property portfolio which already includes composition of matter patent protection for BLU-5937 in all major pharmaceutical markets (U.S., Europe , Japan and China ) until 2034.

  • Simply Wall St.9 months ago

    What Does BELLUS Health Inc’s (TSE:BLU) Ownership Structure Look Like?

    A look at the shareholders of BELLUS Health Inc (TSE:BLU) can tell us which group is most powerful. Institutions will often hold stock in bigger companies, and we expect to Read More...